Blue Trust Inc. Raises Holdings in 10x Genomics $TXG

Blue Trust Inc. boosted its stake in shares of 10x Genomics (NASDAQ:TXG) by 48.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,894 shares of the company’s stock after purchasing an additional 1,590 shares during the quarter. Blue Trust Inc.’s holdings in 10x Genomics were worth $57,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of TXG. GAMMA Investing LLC increased its holdings in 10x Genomics by 1,487.5% during the 1st quarter. GAMMA Investing LLC now owns 31,306 shares of the company’s stock worth $273,000 after purchasing an additional 29,334 shares during the period. SG Americas Securities LLC increased its holdings in 10x Genomics by 12.8% during the 1st quarter. SG Americas Securities LLC now owns 82,406 shares of the company’s stock worth $719,000 after purchasing an additional 9,360 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in 10x Genomics by 9.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,061 shares of the company’s stock worth $271,000 after purchasing an additional 2,564 shares during the period. Diversified Trust Co increased its holdings in 10x Genomics by 60.8% during the 1st quarter. Diversified Trust Co now owns 57,236 shares of the company’s stock worth $500,000 after purchasing an additional 21,634 shares during the period. Finally, Summit Trail Advisors LLC increased its holdings in shares of 10x Genomics by 251.1% in the 1st quarter. Summit Trail Advisors LLC now owns 36,039 shares of the company’s stock valued at $315,000 after acquiring an additional 25,775 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer directly owned 309,273 shares in the company, valued at approximately $4,264,874.67. This trade represents a 6.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares in the company, valued at $6,079,845.52. This trade represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,149 shares of company stock worth $539,865. 9.39% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TXG shares. Zacks Research upgraded 10x Genomics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a report on Tuesday, October 14th. Piper Sandler started coverage on 10x Genomics in a report on Thursday, September 11th. They issued a “neutral” rating and a $15.00 price objective on the stock. Wall Street Zen upgraded 10x Genomics from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Finally, Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $13.65.

10x Genomics Stock Down 4.4%

NASDAQ:TXG opened at $11.83 on Friday. The stock’s 50 day moving average price is $12.87 and its 200 day moving average price is $11.16. The company has a market capitalization of $1.47 billion, a PE ratio of -16.90 and a beta of 2.05. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $18.21.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The firm had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, sell-side analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.